Search PubMed⌕ Search

Biomedical subjects

M B Hansen

Publications and source records attributed to M B Hansen.

115 records · Page 7Linked to original sources
PubMed1989

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

The tetrazolium salt (MTT) method involving conversion of MTT to coloured formazan by cells serving as indirect measurements of cell growth/cell kill has been reported by several groups, although technical problems have been encountered. The present investigation was undertaken in order to delineate what laboratory variables have direct influence on the sensitivity and reproducibility of the method. The pH of the extraction buffer was of the utmost importance, since it was demonstrated that a pH greater than 5 would give rise to false signals. Furthermore, modifying the composition of the extraction buffer, all formazan dye grains were solubilised, totally. A direct comparison with published methods demonstrated that only the modified method would yield 100% higher signals without increasing the background. In contrast to previous reports, it was shown that phenol red does not interfere with the measurements and no washing steps are required since all ingredients can be added subsequently. Serum proteins at concentrations up to 25% have no influence on the result. All samples can be measured in an ELISA scanner at 570 nm with little intra-assay variation.

Animals↗
PubMed1989

Serotonin-induced chloride secretion in hen colon. Possible second messengers.

1. Serotonin, 100 microM, induces a peak increase in short circuit current of about 150 microA/cm2 and in cord conductance of about 7 mS/cm2 and a more prolonged increase of 30 microA/cm2 and 1.4 mS/cm2 which lasts more than 30 min in hen colon. 2. The peak increase in short circuit current and cord conductance is due to a concomitant Cl- secretion. 3. The second messenger, which mediates Cl- secretion, increases in short circuit current and cord conductance, is cyclic AMP as theophylline, 0.5 mM, increases the response in short circuit current to 1 microM serotonin from 38 +/- 5 to 78 +/- 8 microA/cm2 and in g from 1.1 +/- 0.4 to 2.0 +/- 0.3 mS/cm2. 4. Theophylline, 0.5 mM, also sensitizes the hen colon to cyclic AMP yielding an EC50 of 0.24 +/- 0.03 mM in the presence of theophylline compared with an EC50 of 2.3 +/- 0.2 mM in the absence of theophylline. 5. Manipulations of other putative second messenger systems, such as the prostaglandins/leucotrienes, the phosphoinositides and external Ca2+ or calmodulin-sensitive enzymes, did not influence the serotonin response in short circuit current and cord conductance, thus ruling out their importance as intracellular mediators.

Animals↗
PubMed1989

Serotonin receptors for chloride secretion in hen colon.

1. The effect of serotonin on chloride secretion in hen colon was studied under short circuit conditions. 2. Serotonin added to the serosal side induced a short-lived peak increase in Cl(-)-secretion (6.2 +/- 1.0 mumole.cm-2.h-1), in short circuit current (5.4 +/- 0.7 mumole.cm-2.h-1) and in cord conductance (8.1 +/- 0.7 mS.cm-2) with an apparent EC50 around 8 microM, and a more prolonged rise in chloride secretion of around 3.0 mumole.cm-2.h-1. 3. The short circuit current is a reasonable measure of net chloride secretion at the peak. 4. Several specific and non-specific serotonin receptor antagonists were studied for their influence on the serotonin induced peak response in short circuit current and cord conductance. 5. These antagonists covered the whole range of currently defined serotonin receptor types and subtypes: 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, 5-HT2, and 5-HT3. 6. Adrenergic, cholinergic and histaminergic receptor antagonists were also tested for an interaction at the serotonin receptor involved in Ca(-)-secretion. 7. None of the antagonists had any influence on the serotonin response in short circuit current or cord conductance.

Animals↗
PubMedDate not supplied

Cytokine production ex vivo: effect of raised body temperature.

This study was designed to examine the effects of hyperthermia in humans on the production of interleukin (IL)-1 alpha, IL-1 beta, tumour necrosis factor (TNF)beta and interferon (IFN)gamma, determined in supernatants from in vitro lipopolysaccharide or phytohemagglutinin stimulated blood mononuclear cells (BMNC), including the effect of indomethacin in the assays on these cytokines. Eight healthy volunteers were immersed into a hot water bath (water temperature 39.5 degrees C) for 2 h, during which their rectal temperature rose to 39.5 degrees C. On a later day they served as their own controls, being immersed into thermoneutral water (34.5 degrees C) for 2 h. Blood samples were collected before, at body temperatures of 38, 39 and 39.5 degrees C, and 2 h after water immersion and at corresponding time points in the control experiment. Hyperthermia did not influence the production of cytokines from stimulated BMNC. Indomethacin in the assays significantly enhanced the ex vivo production of TNF beta at hyperthermic and thermoneutral conditions; this indomethacin enhanced production of TNF beta declined from pre-value in the hyperthermia experiment compared to the control experiment. Furthermore, indomethacin augmented the production of IFN gamma from stimulated BMNC both in the hyperthermic and the control experiments; the indomethacin effect was, however, not different at the two conditions. It is suggested that hyperthermia alters the sensitivity of BMNC to prostaglandins.

Adult↗
PubMedDate not supplied

TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.

BACKGROUND: Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory juvenile idiopathic arthritis (JIA). For unknown reasons, however, a number of JIA patients fail to respond to this therapy. During this treatment neutralisation of tumour necrosis factor (TNF, previously termed TNF alpha) and lymphotoxin (LT, previously termed TNF beta) may be mediated by etanercept itself as well as by naturally occurring soluble TNF receptors. In light of this, it was of interest to study the total TNF neutralizing capacity in plasma before and during treatment with etanercept. RESULTS: In initial experiments plasma samples from healthy individuals were incubated with etanercept, and spiked with TNF or LT to a final concentration of 1000 pg/mL. Detection of TNF and LT by ELISA was found to be reduced by approximately 50% and 80% respectively, at a concentration of etanercept of 5-500 ng/mL, which is close to the pharmacological plasma concentrations. Plasma samples (n = 80) were then collected from 12 JIA patients (5 with pauciarticular, 5 with polyarticular and 2 with the systemic onset type) during treatment with etanercept (0.4 mg/kg twice weekly) for a period of 20.8 (15.6-23.9) months (median, range). The plasma samples were spiked with LT, and the inhibition of LT detection in ELISA was measured. In samples obtained 3 months after the start of etanercept, the inhibition of LT detection was augmented [72% (60-85)] compared with pre-treatment samples [16% (0.32)] (p = 0.0039). These findings were confirmed in binding assays using radiolabelled TNF. Among patients who responded insufficiently to therapy, reduced LT binding capacity, coinciding with flares of disease activity, was observed. CONCLUSION: We have developed an assay by which LT binding capacity, reflecting the level of free, pharmacologically active etanercept, may be monitored in the blood of patients treated with etanercept. This assay may prove to be useful in guiding dose adjustments in patients with an incomplete response to etanercept.

Adolescent↗